» Read discussion on Teva Pharmaceuticals 06/28/11 CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine®, the Company's flagship cancer immunotherapy.
06/14/11 Patent protection and product pipelines are top priorities for every pharmaceutical manufacturer, which is why Pfizer Inc. and Teva Pharmaceuticals International Ltd. will be in federal court in Norfolk, Va., starting Wednesday as Pfizer fights to keep exclusive rights to Viagra through 2019.
05/02/11 Generic drugmaker Teva Pharmaceuticals will expand its presence in Pennsylvania with the $6.8 billion purchase of Cephalon Inc.
10/29/10 Teva Pharmaceuticals USA said Thursday that $4.7 million in state aid helped persuade the pharmaceutical giant to put its new distribution facility in Philadelphia's Bustleton neighborhood, where the company hopes to employ 500 people in the next five years.
10/28/10 Teva Pharmaceuticals USA, the American arm of the Israeli company that is the world's largest generic-drug maker, will create 200 jobs at a distribution facility it plans to open in Northeast Philadelphia.
10/28/10 Teva Pharmaceuticals USA said Thursday that $4.7 million in state aid helped convince the pharmaceutical giant to put its new distribution facility in Philadelphia's Somerton neighborhood, where the company hopes to employ 500 people in the next five years.
10/27/10 Teva Pharmaceuticals USA will announce on Thursday that it will build a $295 million distribution center and U.S. headquarters on Red Lion Road in Northeast Philadelphia, Rep. Allyson Schwartz (D., Pa.) said today.
10/27/10 Teva Pharmaceuticals USA will announce on Thursday that it will build a $295 million distribution and warehouse center on Red Lion Road in Northeast Philadelphia, Rep. Allyson Schwartz (D., Pa.) said today.
08/12/10 Five new members were recently elected to serve on the board of trustees of University of the Sciences in Philadelphia. Andrew Ferrara, Boston Healthcare; Dr. Leonard S. Jacob, Life Science Advisors; William S. Marth, Teva Pharmaceuticals-The Americas; and Mark Oley, Westwood Pharmacy, will serve as members at-large, while Rose Mary B. Hoy, Merck, is the alumni representative.
06/15/10 Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi??. ? Teva's product is sold as a generic version of Bayer HealthCare's leading oral ...
04/26/10 Teva Pharmaceuticals USA announced Friday that they will be changing operations at their plant in Sellersville, Pa.
04/01/10 Sanofi-Aventis has settled three patent infringement lawsuits in the U.S. related to generic versions of colon cancer treatment Eloxatin, the French drug maker said Thursday. Under terms of the settlements, the three generic drug makers _ Teva Pharmaceuticals... Sanofi-Aventis - Teva Pharmaceutical Industries - Generic drug - Colorectal cancer - Patent infringement
03/09/10 Montgomery Township supervisors talked Monday night about the plans for Teva Pharmaceuticals' new North American headquarters.
01/27/10 Merck & Co, Inc announced that the US District Court for the District of Delaware ruled against the company in a patent infringement suit against Teva Pharmaceuticals USA Inc.
01/14/10 Teva Pharmaceuticals USA, the generic drugmaker with headquarters in North Wales, has proposed a warehouse and office campus on 156 acres in the Eureka Village section of Warrington, Bucks County, Warrington and Teva officials say.
01/14/10 Teva Pharmaceuticals USA, the maker of generic drugs with headquarters in North Wales, has proposed a warehouse and office campus on 156 acres in the Eureka Village section of Warrington, Bucks County, Warrington and Teva officials say.
12/05/09 Cephalon, Inc has filed a lawsuit in US District Court in Delaware against Teva Pharmaceuticals USA, Inc for infringement of US Patent Nos. 7,132,570 (the "'570 Patent"), 7,297,346 (the "'346 Patent") and RE37,516 (the "'516 Patent") for the Cephalon product Nuvigil (armodafinil) Tablets [C-IV].
10/21/09 Cephalon, Inc. today announced receipt of a Paragraph IV Certification Notice Letter on October 20, 2009 regarding an Abbreviated New Drug Application submitted to the U.S. Food and Drug Administration by Teva Pharmaceuticals USA, Inc. requesting approval to market and sell a generic version of the 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths of NUVIGIL® Tablets [C-IV ].
09/24/09 The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's (NYSE: LLY) method-of-use patents on Evista(R) (raloxifene HCl tablets). In the case of Eli Lilly and Company v. Teva Pharmaceuticals Industries Ltd., the court ruled in favor of Lilly on all accounts for these method-of-use patents, including the patent doctrines of obviousness, enablement, and ...
08/20/09 Merck & Co, Inc announced that the US District Court for the District of New Jersey has ruled in Merck's favour in a patent infringement suit against Teva Pharmaceuticals USA Inc. (Teva). Teva was seeking FDA approval to sell a generic version of 4, 5 and 10 mg tablets of Singulair (montelukast sodium), Merck's asthma and allergic rhinitis medicine. | 
